Regeneron Pharmaceuticals (NASDAQ:REGN) Releases Quarterly Earnings Results, Beats Expectations By $0.70 EPS

Regeneron Pharmaceuticals (NASDAQ:REGN) released its quarterly earnings data on Friday. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating the consensus estimate of $10.74 by $0.70, FiscalAI reports. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the business posted $12.07 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% compared to the same quarter last year.

Here are the key takeaways from Regeneron Pharmaceuticals’ conference call:

• Dupixent momentum continued with global Q4 net sales of $4.9B ($17.8B FY2025) and >1.4M patients on therapy, supporting continued near‑ and long‑term growth across underpenetrated indications.
• EYLEA HD shows strong commercial traction (U.S. Q4 +66%) and a prefilled‑syringe FDA review with a decision expected in late April, but legacy EYLEA 2 mg faces looming U.S. biosimilar launches and elevated wholesaler inventory that may depress Q1 sales.
• Regeneron expects multiple near‑term clinical and regulatory catalysts — including at least four FDA approvals, pivotal readouts for fianlimab+Libtayo, Linvoseltamab expansion, cemdisiran/pozelimab in PNH, and GA interim data — underpinning pipeline‑driven upside.
• 2026 guidance shows materially higher investment (R&D $5.9–6.1B; SG&A $2.5–2.65B; capex $1.1–1.3B) while maintaining capital returns (quarterly dividend $0.94; $1.5B buyback remaining), signaling balanced longer‑term growth focus but near‑term margin pressure.
• Regeneron is in active negotiations with U.S. government agencies on drug‑pricing measures and expects to reach an agreement consistent with recent industry frameworks, which could introduce downside risk to U.S. pricing and revenues depending on final terms.

Regeneron Pharmaceuticals Stock Down 1.1%

REGN opened at $741.45 on Friday. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The firm has a market capitalization of $77.93 billion, a P/E ratio of 17.76, a PEG ratio of 1.95 and a beta of 0.39. The company’s 50-day moving average is $758.39 and its 200 day moving average is $650.56. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be issued a $0.94 dividend. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Insider Activity

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.02% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. IHT Wealth Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 3.7% during the 2nd quarter. IHT Wealth Management LLC now owns 643 shares of the biopharmaceutical company’s stock worth $338,000 after purchasing an additional 23 shares during the period. Geneos Wealth Management Inc. increased its holdings in Regeneron Pharmaceuticals by 3.0% during the second quarter. Geneos Wealth Management Inc. now owns 780 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 23 shares during the last quarter. Paces Ferry Wealth Advisors LLC raised its position in Regeneron Pharmaceuticals by 5.4% in the second quarter. Paces Ferry Wealth Advisors LLC now owns 548 shares of the biopharmaceutical company’s stock worth $288,000 after acquiring an additional 28 shares during the period. Fairfield Bush & CO. boosted its stake in Regeneron Pharmaceuticals by 1.4% in the second quarter. Fairfield Bush & CO. now owns 2,187 shares of the biopharmaceutical company’s stock valued at $1,148,000 after acquiring an additional 30 shares during the last quarter. Finally, Fred Alger Management LLC grew its position in shares of Regeneron Pharmaceuticals by 6.7% during the 3rd quarter. Fred Alger Management LLC now owns 513 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 32 shares during the period. Institutional investors own 83.31% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Company beat Q4 revenue and EPS estimates (qtrly revenue $3.88B; EPS $11.44 vs. consensus ~$10.74), helped by Dupixent and Eylea HD sales — a near-term fundamental driver supporting the stock. GlobeNewswire – Q4 Results
• Positive Sentiment: Board raised the quarterly dividend to $0.94 (a ~6.8% increase vs. prior $0.88), signaling confidence in cash flow and making the stock slightly more attractive to income-focused investors.
• Positive Sentiment: Analyst optimism persists — Raymond James reiterated a Buy and set an $870 target; Evercore/ISI and others have also lifted targets, which can support demand on dips. TipRanks – Raymond James
• Positive Sentiment: Pipeline update: management highlighted an experimental obesity drug with added cholesterol-lowering benefits that could differentiate it in a crowded market — a potential medium-term growth driver. Reuters – Obesity drug story
• Neutral Sentiment: Full earnings materials and the Q4 earnings call transcript are available for deeper detail — useful for investors who want guidance commentary and pipeline timing. Seeking Alpha – Call Transcript
• Negative Sentiment: Despite the beats, EPS declined year-over-year (from $12.07 to $11.44) as higher expenses weighed on profitability — a headline that likely pressured sentiment. Reuters – Profit beat but EPS down YoY
• Negative Sentiment: Core Eylea weakness and investor concerns about sustainability of growth prompted some sell-side caution and profit-taking even after the beat, which helps explain the share decline today. MSN – Why shares fell

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Hsbc Global Res upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Wells Fargo & Company upped their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. Truist Financial raised their price objective on shares of Regeneron Pharmaceuticals from $798.00 to $820.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 29th. Finally, Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 8th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $784.77.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.